Image Ben Hargreaves R&D R&D in 2023 sees focus return to oncology After the rush of research to find solutions to the pandemic, a recent report has found that pharma R&D has returned to its usual rhythms. Market Access Aduhelm and an expensive failure to launch Biogen’s treatment for Alzheimer’s was initially regarded as a major treatment breakthrough. R&D AI and the battle against AMR One of the largest threats facing public health is growing resistance to the world’s existing antibiotics. Oncology Warning signs for CAR-T after secondary cancer cases CAR-T treatments emerged as a major success for the pharma industry when first approved in 2017, but this has been muddied by concerns over secondary malignancies. Load more results
R&D R&D in 2023 sees focus return to oncology After the rush of research to find solutions to the pandemic, a recent report has found that pharma R&D has returned to its usual rhythms.
Market Access Aduhelm and an expensive failure to launch Biogen’s treatment for Alzheimer’s was initially regarded as a major treatment breakthrough.
R&D AI and the battle against AMR One of the largest threats facing public health is growing resistance to the world’s existing antibiotics.
Oncology Warning signs for CAR-T after secondary cancer cases CAR-T treatments emerged as a major success for the pharma industry when first approved in 2017, but this has been muddied by concerns over secondary malignancies.
News Remepy's hybrid Parkinson's therapy poised for phase 3 Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
